(NASDAQ: EPZM) reported positive interim data from an ongoing Phase 2 trial of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed or refractory
follicular lymphoma who have received at least two prior lines of systemic therapy.
Epizyme reported positive interim data from an ongoing Phase 2 trial of its lead candidate, tazemetostat, as a monotherapy for patients with relapsed or refractory
follicular lymphoma, or FL, who have received at least two prior lines of systemic therapy.
The US Food and Drug Administration (FDA) has granted approval to United States-based Celgene for its Revlimid (lenalidomide) in combination with a rituximab product intended to treat adult patients with earlier treated
follicular lymphoma (FL) or marginal zone lymphoma (MZL), it was reported yesterday.
Global Banking News-October 25, 2018-Nordic Nanovector awarded Promising Innovative Medicine (PIM) designation for Betalutin for advanced relapsed/refractory
follicular lymphomaFollicular lymphoma (FL) is the second most common type of non-Hodgkin lymphoma in the United States.
The study evaluates daratumumab monotherapy in three different types of NHL, diffuse large B-cell lymphoma (DLBCL),
follicular lymphoma (FL) and mantle cell lymphoma (MCL).This milestone is related to progress in the arm of the study treating patients with FL.
[ClickPress, Tue Aug 04 2015] Global Markets Direct's, '
Follicular Lymphoma - Pipeline Review, H1 2015', provides an overview of the
Follicular Lymphoma's therapeutic pipeline.
BeiGene announced results from an ongoing Phase 1b clinical study of its investigational BTK inhibitor zanubrutinib in combination with Gazyva in patients with relapsed/refractory or treatment naive chronic lymphocytic leukemia or small lymphocytic lymphoma, and patients with R/R
follicular lymphoma. The open-label, Phase 1b trial of zanubrutinib in combination with obinutuzumab in patients with B-cell malignancies is being conducted in Australia, the United States, and South Korea, and consists of a dose-escalation phase and a dose-expansion phase in disease-specific cohorts, including patients with TN or R/R CLL/SLL and patients with R/R FL.
The Japan Ministry of Health, Labour and Welfare's (MHLW) orphan drug designation for axicabtagene ciloleucel (formerly KTE-C19) is being reviewed for the treatment of diffuse large B-cell lymphoma (DLBCL), primary mediastinal (thymus) large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma (HGBL) and transformed
follicular lymphoma (TFL), which are aggressive forms of non-Hodgkin lymphoma (NHL).
The 2008 World Health Organization (WHO) lymphoma classification identified primary intestinal
follicular lymphoma as a variant of
follicular lymphoma.